Dear Spiral user, We’re pleased to introduce Helix, https://helix.imperial.ac.uk/ Imperial’s new repository for research datasets. Please use Helix for all future dataset deposits. There is no change to Spiral - continue depositing as usual. For queries, contact the Research Data Management team at rdm-enquiries@imperial.ac.uk. Kind regards, the Spiral Team. The Spiral team
Novel oral polio vaccine type 2 use for polio outbreak response: a global effort for a global health emergency
File(s)
pathogens-13-00273-v2.pdf (3.13 MB)
Published version
Author(s)
Kurji, Feyrouz Damji
Bandyopadhyay, Ananda Sankar
Zipursky, Simona
Cooper, Laura V
Gast, Chris
Type
Journal Article
Abstract
A sharp rise in circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks in the years following the cessation of routine use of poliovirus type 2-containing oral polio vaccine and the trend of seeding new emergences with suboptimal vaccination response during the same time-period led to the accelerated development of the novel oral polio vaccine type 2 (nOPV2), a vaccine with enhanced genetic stability and lower likelihood of reversion to neuroparalytic variants compared to its Sabin counterpart. In November 2020, nOPV2 became the first vaccine to be granted an Emergency Use Listing (EUL) by the World Health Organization (WHO) Prequalification Team (PQT), allowing close to a billion doses to be used by countries within three years after its first rollout and leading to full licensure and WHO prequalification (PQ) in December 2023. The nOPV2 development process exemplifies how scientific advances and innovative tools can be applied to combat global health emergencies in an urgent and adaptive way, building on a collaborative effort among scientific, regulatory and implementation partners and policymakers across the globe.
Date Issued
2024-04
Date Acceptance
2024-03-18
Citation
Pathogens, 2024, 13 (4)
URI
URL
DOI
ISSN
2076-0817
Publisher
MDPI
Journal / Book Title
Pathogens
Volume
13
Issue
4
Copyright Statement
© 2024 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/38668228
PII: pathogens13040273
Subjects
emergency use listing
novel oral poliovirus vaccine
poliovirus
public health emergency of international concern
vaccine
WHO prequalification
Publication Status
Published
Coverage Spatial
Switzerland
Article Number
273
Date Publish Online
2024-03-23